SENSCIS Archives - Medical Conferences

Antifibrotic therapy with nintedanib is beneficial for patients with negative prognostic factors

Presented By

Prof. Christopher Denton , University College London, United Kingdom

Trial

Phase 3, SENSCIS

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 18:07

EULAR 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

EULAR 2022

22 June 2022 23:51

Rheumatoid arthritis and interstitial lung disease: a deadly combination

Presented By

Prof. Joan Bathon, Columbia University, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:59

Antifibrotic therapy slows disease progression independent of corticosteroid use

Presented By

Dr Madelon Vonk, Radboud University, the Netherlands

Trial

SENSCIS

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 23:22

Reduction of FVC decline in systemic sclerosis-associated ILD

Presented By

Dr Kristin Highland, Cleveland Clinic, Ohio, USA

Trial

SENSCIS

Conference

ERS 2019

Type

Peer-reviewed article

28 November 2019 22:14

Interstitial lung disease in rheumatic diseases and systemic sclerosis

Presented By

Dr Jan Grutters, University Medical Center Utrecht, the Netherlands

Trial

SENSCIS, INPULSIS, SLS-2

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 23:50

Nintedanib reduces lung function decline in systemic sclerosis-associated ILD

Presented By

Prof. Oliver Distler, University Hospital Zurich, Switzerland

Trial

SENSCIS

Conference

ATS 2019

Type

Peer-reviewed article

23 July 2019 23:49